Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Pilcher, M. Patel, A. Smith, C. Davies, J. Travers, M. Weatherall, R. Beasley, M. Harwood (Wellington, Lower Hutt, New Zealand; Nottingham, United Kingdom). The budesonide/formoterol inhaler as maintenance and reliever therapy in Maori asthmatics. Eur Respir J 2013; 42: Suppl. 57, 3838

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of budesonide/formoterol maintenance and reliever therapy in mild asthma Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Tiotropium Respimat® add-on therapy in children with symptomatic asthma Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Source: Eur Respir J 2005; 26: 819-828 Year: 2005 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Equivalence of an innovative multidose salmeterol/fluticasone dry powder inhaler vs comparator in paediatric asthma Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013 Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Budesonide/formoterol maintenance and reliever therapy for asthma in general practice: is it cost-effective? Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma Source: Eur Respir J, 51 (1) 1701688; 10.1183/13993003.01688-2017 Year: 2018 Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Comparable effectiveness of budesonide/formoterol combination and fluticasone for the treatment of cough variant asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Real-life effectiveness of budesonide/formoterol for the management of asthma and COPD Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016 Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Tiotropium as add-on to inhaled corticosteroids significantly improves asthma control as reflected by the ACQ responder rate Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 LATE-BREAKING ABSTRACT: Safety and tolerability of once-daily tiotropium Respimat® add-on therapy in children with moderate symptomatic asthma Source: International Congress 2016 – Living with asthma around the globe Year: 2016